Market Intelligence, Clinical Progress, and High-Purity Reagents for Epitranscriptomics and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for YTHDC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | YTHDC1 Recombinant Protein (YTH Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for SPR/FP assays. |
View YTHDC1 Products |
| Gene Delivery | YTHDC1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and intracellular localization studies. |
View YTHDC1 Products |
| Benchmark Ab | Anti-YTHDC1 Recombinant Antibody Recombinant positive control for Western Blot, ChIP, and IP assays. |
View YTHDC1 Products |
| Validator | YTHDC1 siRNA Set For target knockdown verification and functional rescue assays. |
View YTHDC1 Products |
| Related Target A | METTL3 Core m6A methyltransferase ("writer") acting upstream of YTHDC1; critical for synergistic therapeutic targeting. |
View METTL3 Products |
| Related Target B | ALKBH5 m6A demethylase ("eraser") that counteracts YTHDC1-mediated RNA processing; key pathway control. |
View ALKBH5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High-throughput Screening (HTS) of m6A-binding pocket inhibitors | Highly stable YTH domain recombinant proteins with verified sequence and high purity (>95%) for robust FP/TR-FRET assays. |
| Off-target selectivity profiling against other YTH readers (YTHDF1/2/3) | Complete profiling panel of recombinant YTH family proteins with strict batch-to-batch consistency. |
| Lack of validated positive controls for cellular assays | Sequence-verified recombinant antibodies and validated siRNA sets included to ensure assay specificity. |
| Cellular validation of target engagement | High-titer Lentiviral particles for stable overexpression to monitor m6A-dependent RNA splicing and export. |
Live YTHDC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for YTHDC1 therapeutics is intensifying, with major players shifting focus from traditional epitranscriptomic profiling to selective small-molecule inhibitors and PROTAC degraders. As first-generation m6A-pathway therapies (such as METTL3 inhibitors) reach the clinic, the next wave of R&D is targeting YTHDC1 to directly block the reader-mediated nuclear export and splicing of oncogenic transcripts in acute myeloid leukemia (AML) and glioblastoma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Accent Therapeutics, Storm Therapeutics | AML, Solid Tumors (Glioblastoma) | Selectivity Assay (Need Mutant vs WT Proteins & YTH family panels) |
| PROTAC (Degrader) | Academic Spin-offs, Biotech Startups | Refractory Hematological Malignancies | Ubiquitination & Degradation Assay (Need Lentivirus for stable reporter cells) |
| Combination Therapy | Oncology Consortia | Immune-cold Tumors | Synergy Validation (Need METTL3/ALKBH5 companion screening tools) |